Publication:
Cisplatin plus etoposide in the adjuvant treatment of patients with non small cell lung cancer

Simple item page
dc.contributor.authorÇubukcu, Erdem
dc.contributor.authorCanhoroz, Mustafa
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorKanat, Özkan
dc.contributor.authorKurt, Ender
dc.contributor.authorErol, Muharrem
dc.contributor.authorÇubukcu, Sinem
dc.contributor.authorYorulmaz, Nadide
dc.contributor.authorBayram, Sami
dc.contributor.authorEvrensel, Türkkan
dc.contributor.authorManavoğlu, Osman
dc.contributor.buuauthorÇUBUKÇU, ERDEM
dc.contributor.buuauthorCanhoroz, Mustafa
dc.contributor.buuauthorÖlmez, Ömer Fatih
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorErol, Muharrem
dc.contributor.buuauthorÇUBUKÇU, SİNEM
dc.contributor.buuauthorYorulmaz, Nadide
dc.contributor.buuauthorBAYRAM, AHMET SAMİ
dc.contributor.buuauthorEVRENSEL, TÜRKKAN
dc.contributor.buuauthorManavoğlu, Osman
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGöğüs Cerrahisi Ana Bilim Dalı
dc.contributor.orcid0000-0002-9732-5340
dc.contributor.researcheridJGT-4101-2023
dc.contributor.researcheridCJW-6018-2022
dc.contributor.researcheridDJG-4827-2022
dc.contributor.researcheridCYM-0930-2022
dc.contributor.researcheridDAS-3088-2022
dc.contributor.researcheridJEN-3243-2023
dc.contributor.researcheridJJB-0254-2023
dc.contributor.researcheridGKI-1183-2022
dc.contributor.researcheridEMY-5874-2022
dc.contributor.researcheridAAJ-1027-2021
dc.contributor.researcheridFLP-9613-2022
dc.date.accessioned2024-09-19T08:41:44Z
dc.date.available2024-09-19T08:41:44Z
dc.date.issued2014-09-01
dc.description.abstractAim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.
dc.identifier.doi10.4328/JCAM.1469
dc.identifier.endpage416
dc.identifier.issn1309-0720
dc.identifier.issue5
dc.identifier.startpage414
dc.identifier.urihttps://doi.org/10.4328/JCAM.1469
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000215566500018
dc.identifier.urihttps://hdl.handle.net/11452/44927
dc.identifier.volume5
dc.identifier.wos000215566500018
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherDerman Medical Publ
dc.relation.journalJournal of Clinical and Analytical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNonsmall cell lung cancer
dc.subjectAdjuvant chemotherapy
dc.subjectCisplatin
dc.subjectGeneral & internal medicine
dc.titleCisplatin plus etoposide in the adjuvant treatment of patients with non small cell lung cancer
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Göğüs Cerrahisi Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Tıbbi Onkoloji Ana Bilim Dalı
relation.isAuthorOfPublicationf971677f-09c5-4463-bf01-3c6341fbe5f7
relation.isAuthorOfPublication375ef438-7ff8-4a42-97a4-74096fac117f
relation.isAuthorOfPublicationbdb7801d-f0bc-4abc-af2c-5bf7df23fbd5
relation.isAuthorOfPublicationeceff514-6af7-4c3b-a146-b77546565a6c
relation.isAuthorOfPublication.latestForDiscoveryf971677f-09c5-4463-bf01-3c6341fbe5f7

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Cubukcu_vd_2014.pdf
Size:
502.92 KB
Format:
Adobe Portable Document Format
Download

Collections

Yeni Yayınlar